title: [Mycotic liver and spleen abscesses successfully treated by intraportal and intrahepatosplenic arterial administration of antimycotic drugs in two cases with acute leukemia].
abstract: Case 1. A 34-year-old male was admitted in July, 1986 with a diagnosis of AML (M2). Two courses of BHAC-DMP regimen induced complete remission in October, while marked pyrexia resistant to antibiotics remained. An ultrasonography (US) and computed tomography (CT) revealed multiple liver and spleen abscesses suspected of mycotic etiology. Administration of amphotericin B (AMPH-B) by intravenous injection was difficult owing to its severe side effect. Multiple abscesses increased in the size and number despite treatment with Miconazole (MCZ) and Ketoconazole. Exploratory laparotomy was performed with splenectomy, and splenic specimens were found to contain Candida organisms. Soon AMPH-B was administered through a catheter inserted into the portal vein at the same time. A side effect by AMPH-B was tolerable and his fever resolved to normal in 2 weeks after institution of this therapy, and the sizes of abscesses were markedly reduced. The patient remained in remission through 23 months, free of fungal infection. Case 2. A 23-year-old female was admitted for relapse of ALL (L2), in April, 1987. Reinduction therapy with BHAC-L-AVP achieved again in May but fever unresponsive to antibiotics occurred. Since multiple liver-spleen abscesses were showed by US and CT suspected mycotic etiology, antimycotic therapy with Miconazole and AMPH-B was performed but clinical findings were deteriorated. AMPH-B was administered through a catheter inserted into the hepatic artery for two weeks, following into the splenic artery for a week. Splenic abscesses were resolved in a week and liver abscesses were markedly reduced at three weeks after initiation of intra-arterial antifungal treatment. Through the analysis of these case studies we confirmed the usefulness of intraportal and intrahepatosplenic arterial administration of AMPH-B.
authors.forename: T
authors.initials: T
authors.lastname: Chujo
authors.forename: H
authors.initials: H
authors.lastname: Kuratsune
authors.forename: Y
authors.initials: Y
authors.lastname: Nishimori
authors.forename: T
authors.initials: T
authors.lastname: Machii
authors.forename: T
authors.initials: T
authors.lastname: Kitani
authors.forename: Y
authors.initials: Y
authors.lastname: Kimoto
authors.forename: T
authors.initials: T
authors.lastname: Hashimoto
authors.forename: H
authors.initials: H
authors.lastname: Nakamura
authors.forename: K
authors.initials: K
authors.lastname: Aozasa
mesh_terms: D000038:Abscess / Q000150:complications / Q000188:drug therapy*; D000208:Acute Disease; D000328:Adult; D000666:Amphotericin B / Q000008:administration & dosage* / Q000627:therapeutic use; D002408:Catheters, Indwelling; D005260:Female; D006499:Hepatic Artery; D006801:Humans; D007938:Leukemia / Q000150:complications*; D008100:Liver Abscess / Q000150:complications / Q000188:drug therapy*; D008297:Male; D009181:Mycoses / Q000150:complications / Q000188:drug therapy*; D011169:Portal Vein; D013157:Splenic Artery; D013158:Splenic Diseases / Q000150:complications / Q000188:drug therapy*
chemical_list: D000666:Amphotericin B